secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263540
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025
---------------------------------------------------------------

- Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.
- Cash $978.7M as of Sept 30; runway into H2 2028 beyond multiple pipeline milestones.
- KT-621 Phase 1b AD trial (BroADen) enrollment complete; top-line data expected Dec 2025.
- KT-621 Phase 2b AD trial (BROADEN2) initiated; asthma Phase 2b (BREADTH) on track for 1Q26.
- KT-579 (IRF5) IND-enabling studies completed; Phase 1 planned for early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/0001193125-25-263540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/kymr-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer